Academic Journal
Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial
| العنوان: | Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial |
|---|---|
| المؤلفون: | Mahadeo, Kris Michael, Baiocchi, Robert, Beitinjaneh, Amer, Chaganti, Sridhar, Choquet, Sylvain, Dierickx, Daan, Dinavahi, Rajani, Duan, Xinyuan, Gamelin, Laurence, Ghobadi, Armin, Guzman-Becerra, Norma, Joshi, Manher, Mehta, Aditi, Navarro, Willis H, Nikiforow, Sarah, O'Reilly, Richard J, Reshef, Ran, Ruiz, Fiona, Spindler, Tassja, Prockop, Susan |
| المساهمون: | National Comprehensive Cancer Network, Atara Biotherapeutics |
| المصدر: | The Lancet Oncology ; volume 25, issue 3, page 376-387 ; ISSN 1470-2045 |
| بيانات النشر: | Elsevier BV |
| سنة النشر: | 2024 |
| المجموعة: | ScienceDirect (Elsevier - Open Access Articles via Crossref) |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1016/s1470-2045(23)00649-6 |
| الاتاحة: | http://dx.doi.org/10.1016/s1470-2045(23)00649-6 https://api.elsevier.com/content/article/PII:S1470204523006496?httpAccept=text/xml https://api.elsevier.com/content/article/PII:S1470204523006496?httpAccept=text/plain |
| Rights: | https://www.elsevier.com/tdm/userlicense/1.0/ ; https://doi.org/10.15223/policy-017 ; https://doi.org/10.15223/policy-037 ; https://doi.org/10.15223/policy-012 ; https://doi.org/10.15223/policy-029 ; https://doi.org/10.15223/policy-004 |
| رقم الانضمام: | edsbas.98D0166A |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/s1470-2045(23)00649-6 |
|---|